{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:43:51Z","timestamp":1778499831772,"version":"3.51.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s13023-014-0122-8","type":"journal-article","created":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T09:09:35Z","timestamp":1407143375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Systemic therapy of Cushing\u2019s syndrome"],"prefix":"10.1186","volume":"9","author":[{"given":"Niels","family":"Eckstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodo","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz David Sebastian","family":"Hass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladlena","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"122_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jc.2003-030440","volume":"89","author":"JQ Purnell","year":"2004","unstructured":"Purnell JQ, Brandon DD, Isabelle LM, Loriaux DL, Samuels MH: Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab. 2004, 89: 281-287. 10.1210\/jc.2003-030440.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR2","first-page":"450","volume":"10","author":"S Jackman","year":"2013","unstructured":"Jackman S, Diamond F: Pituitary adenomas in childhood and adolescence. Pediatr Endocrinol Rev. 2013, 10: 450-459.","journal-title":"Pediatr Endocrinol Rev"},{"key":"122_CR3","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1530\/EJE-13-0534","volume":"169","author":"O Ragnarsson","year":"2013","unstructured":"Ragnarsson O, Johannsson G: Cushing\u2019s syndrome: a structured short- and long-term management plan for patients in remission. Eur J Endocrinol. 2013, 169: R139-R152. 10.1530\/EJE-13-0534.","journal-title":"Eur J Endocrinol"},{"key":"122_CR4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","volume":"9","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Giustina A: Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol. 2013, 9: 265-276.","journal-title":"Nat Rev Endocrinol"},{"key":"122_CR5","first-page":"319","volume":"88","author":"MG Lake","year":"2013","unstructured":"Lake MG, Krook LS, Cruz SV: Pituitary adenomas: an overview. Am Fam Physician. 2013, 88: 319-327.","journal-title":"Am Fam Physician"},{"key":"122_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cncr.23542","volume":"113","author":"BI Gustafsson","year":"2008","unstructured":"Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer. 2008, 113: 5-21. 10.1002\/cncr.23542.","journal-title":"Cancer"},{"key":"122_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1746-1596-5-56","volume":"5","author":"S Shahani","year":"2010","unstructured":"Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL: Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol. 2010, 5: 56-10.1186\/1746-1596-5-56.","journal-title":"Diagn Pathol"},{"key":"122_CR8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MED.0b013e32814db842","volume":"14","author":"I Bourdeau","year":"2007","unstructured":"Bourdeau I, Lampron A, Costa MH, Tadjine M, Lacroix A: Adrenocorticotropic hormone-independent Cushing\u2019s syndrome. Curr Opin Endocrinol Diabetes Obes. 2007, 14: 219-225. 10.1097\/MED.0b013e32814db842.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"122_CR9","doi-asserted-by":"crossref","first-page":"W541","DOI":"10.2214\/AJR.09.4056","volume":"194","author":"N Courcoutsakis","year":"2010","unstructured":"Courcoutsakis N, Prassopoulos P, Stratakis CA: CT findings of primary pigmented nodular adrenocortical disease: rare cause of ACTH-independent Cushing syndrome. AJR Am J Roentgenol. 2010, 194: W541-10.2214\/AJR.09.4056.","journal-title":"AJR Am J Roentgenol"},{"key":"122_CR10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4158\/EP12277.RA","volume":"19","author":"A Maghrabi","year":"2013","unstructured":"Maghrabi A, Yaqub A, Denning KL, Benhamed N, Faiz S, Saleem T: Challenges in the diagnostic work-up and management of patients with subclinical Cushing\u2019s syndrome and bilateral adrenal masses. Endocr Pract. 2013, 19: 515-521. 10.4158\/EP12277.RA.","journal-title":"Endocr Pract"},{"key":"122_CR11","unstructured":"European Commission, Communitiy register of medicinal products. , : [ http:\/\/ec.europa.eu\/health\/documents\/community-register\/ ]"},{"key":"122_CR12","unstructured":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council on Orphan Medicinal Products. ,:, [ http:\/\/eur-lex.europa.eu\/ ]"},{"key":"122_CR13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM: The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011, 165: 383-392. 10.1530\/EJE-11-0272.","journal-title":"Eur J Endocrinol"},{"key":"122_CR14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cen.12094","volume":"78","author":"R van der Pas","year":"2013","unstructured":"van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA: Hypercoagulability in Cushing\u2019s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf). 2013, 78: 481-488. 10.1111\/cen.12094.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"122_CR15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0002-9343(52)90027-2","volume":"13","author":"CM Plotz","year":"1952","unstructured":"Plotz CM, Knowlton AI, Ragan C: The natural history of Cushing\u2019s syndrome. Am J Med. 1952, 13: 597-614. 10.1016\/0002-9343(52)90027-2.","journal-title":"Am J Med"},{"key":"122_CR16","doi-asserted-by":"crossref","first-page":"f945","DOI":"10.1136\/bmj.f945","volume":"346","author":"JK Prague","year":"2013","unstructured":"Prague JK, May S, Whitelaw BC: Cushing\u2019s syndrome. BMJ. 2013, 346: f945-10.1136\/bmj.f945.","journal-title":"BMJ"},{"key":"122_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0030-1263104","volume":"119","author":"T Psaras","year":"2011","unstructured":"Psaras T, Milian M, Hattermann V, Freiman T, Gallwitz B, Honegger J: Demographic factors and the presence of comorbidities do not promote early detection of Cushing\u2019s disease and acromegaly. Exp Clin Endocrinol Diabetes. 2011, 119: 21-25. 10.1055\/s-0030-1263104.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"122_CR18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(82)92749-0","volume":"2","author":"EJ Ross","year":"1982","unstructured":"Ross EJ, Linch DC: Cushing\u2019s syndrome\u2013killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982, 2: 646-649. 10.1016\/S0140-6736(82)92749-0.","journal-title":"Lancet"},{"key":"122_CR19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA, Pulgar SJ, Kempel A, Pereira AM: The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012, 167: 311-326. 10.1530\/EJE-11-1095.","journal-title":"Eur J Endocrinol"},{"key":"122_CR20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-13-0569","volume":"169","author":"G Ntali","year":"2013","unstructured":"Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N: Mortality in Cushing\u2019s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013, 169: 715-723. 10.1530\/EJE-13-0569.","journal-title":"Eur J Endocrinol"},{"key":"122_CR21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejim.2011.10.013","volume":"23","author":"D Graversen","year":"2012","unstructured":"Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO: Mortality in Cushing\u2019s syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012, 23: 278-282. 10.1016\/j.ejim.2011.10.013.","journal-title":"Eur J Intern Med"},{"key":"122_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","volume":"157","author":"L Fardet","year":"2007","unstructured":"Fardet L, Flahault A, Kettaneh A, Tiev KP, Genereau T, Toledano C, Lebb\u00e9 C, Cabane J: Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion. Br J Dermatol. 2007, 157: 142-148. 10.1111\/j.1365-2133.2007.07950.x.","journal-title":"Br J Dermatol"},{"key":"122_CR23","first-page":"117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, J\u00f8rgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J: Incidence and late prognosis of cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab. 2001, 86: 117-123.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing\u2019s syndrome. Lancet. 2006, 367: 1605-1617. 10.1016\/S0140-6736(06)68699-6.","journal-title":"Lancet"},{"key":"122_CR25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"Etxabe J, Vazquez JA: Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994, 40: 479-484. 10.1111\/j.1365-2265.1994.tb02486.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"122_CR26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nec.2012.06.012","volume":"23","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M: Medical management of persistent and recurrent cushing disease. Neurosurg Clin N Am. 2012, 23: 653-668. 10.1016\/j.nec.2012.06.012.","journal-title":"Neurosurg Clin N Am"},{"key":"122_CR27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0033-1345688","volume":"75","author":"M Bodaghabadi","year":"2014","unstructured":"Bodaghabadi M, Riazi H, Aran S, Bitaraf MA, Alikhani M, Alahverdi M, Mohamadi M, Shalileh K, Azar M: Repeated transsphenoidal surgery or gamma knife radiosurgery in recurrent cushing disease after transsphenoidal surgery. J Neurol Surg A Cent Eur Neurosurg. 2014, 75: 91-97.","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"key":"122_CR28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003088-200342070-00003","volume":"42","author":"DP Del","year":"2003","unstructured":"Del DP, Bonuccelli U: Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003, 42: 633-645. 10.2165\/00003088-200342070-00003.","journal-title":"Clin Pharmacokinet"},{"key":"122_CR29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01735795","volume":"66","author":"B Allolio","year":"1988","unstructured":"Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W: Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing\u2019s syndrome. Klin Wochenschr. 1988, 66: 361-364. 10.1007\/BF01735795.","journal-title":"Klin Wochenschr"},{"key":"122_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0746","volume":"167","author":"VA Preda","year":"2012","unstructured":"Preda VA, Sen J, Karavitaki N, Grossman AB: Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review. Eur J Endocrinol. 2012, 167: 137-143. 10.1530\/EJE-12-0746.","journal-title":"Eur J Endocrinol"},{"key":"122_CR31","unstructured":"European Public Assessment Report - Scientific Discussion of Lysodren. 2005, EMEA\/H\/C\/000521, London"},{"key":"122_CR32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","volume":"81","author":"M Brada","year":"1999","unstructured":"Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999, 81: 1022-1030. 10.1038\/sj.bjc.6690802.","journal-title":"Br J Cancer"},{"key":"122_CR33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0015-0282(16)60067-5","volume":"50","author":"JH Liu","year":"1988","unstructured":"Liu JH, Garzo VG, Yen SS: Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. Fertil Steril. 1988, 50: 245-249.","journal-title":"Fertil Steril"},{"key":"122_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1750-1172-7-41","volume":"7","author":"F Castinetti","year":"2012","unstructured":"Castinetti F, Morange I, Conte-Devolx B, Brue T: Cushing\u2019s disease. Orphanet J Rare Dis. 2012, 7: 41-10.1186\/1750-1172-7-41.","journal-title":"Orphanet J Rare Dis"},{"key":"122_CR35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0022-4731(89)90008-3","volume":"32","author":"O Heikinheimo","year":"1989","unstructured":"Heikinheimo O: Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem. 1989, 32: 21-25. 10.1016\/0022-4731(89)90008-3.","journal-title":"J Steroid Biochem"},{"key":"122_CR36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12020-012-9668-1","volume":"42","author":"C Beglinger","year":"2012","unstructured":"Beglinger C, Hu K, Wang Y, Bouillaud E, Darstein C, Wang Y, Mohideen P: Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine. 2012, 42: 366-374. 10.1007\/s12020-012-9668-1.","journal-title":"Endocrine"},{"key":"122_CR37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.1966.03110220091030","volume":"198","author":"DE Schteingart","year":"1966","unstructured":"Schteingart DE, Cash R, Conn JW: Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing\u2019s syndrome. JAMA. 1966, 198: 1007-1010. 10.1001\/jama.1966.03110220091030.","journal-title":"JAMA"},{"key":"122_CR38","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/jcem-27-12-1657","volume":"27","author":"DE Schteingart","year":"1967","unstructured":"Schteingart DE, Conn JW: Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing\u2019s syndrome. J Clin Endocrinol Metab. 1967, 27: 1657-1666. 10.1210\/jcem-27-12-1657.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/acta.0.1090451","volume":"109","author":"M Thoren","year":"1985","unstructured":"Thoren M, Adamson U, Sjoberg HE: Aminoglutethimide and metyrapone in the management of Cushing\u2019s syndrome. Acta Endocrinol (Copenh). 1985, 109: 451-457.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"122_CR40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1055\/s-0031-1287769","volume":"43","author":"MD Culler","year":"2011","unstructured":"Culler MD: Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Horm Metab Res. 2011, 43: 854-857. 10.1055\/s-0031-1287769.","journal-title":"Horm Metab Res"},{"key":"122_CR41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","volume":"10","author":"C de Bruin","year":"2009","unstructured":"de Bruin C, Feelders RA, Lamberts SW, Hofland LJ: Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s syndrome. Rev Endocr Metab Disord. 2009, 10: 91-102. 10.1007\/s11154-008-9082-4.","journal-title":"Rev Endocr Metab Disord"},{"key":"122_CR42","first-page":"286","volume":"55","author":"JM Gooding","year":"1976","unstructured":"Gooding JM, Corssen G: Etomidate: an ultrashort-acting nonbarbiturate agent for anesthesia induction. Anesth Analg. 1976, 55: 286-289.","journal-title":"Anesth Analg"},{"key":"122_CR43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/ALN.0b013e3181ff72b5","volume":"114","author":"SA Forman","year":"2011","unstructured":"Forman SA: Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011, 114: 695-707. 10.1097\/ALN.0b013e3181ff72b5.","journal-title":"Anesthesiology"},{"key":"122_CR44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2044.1984.tb08885.x","volume":"39","author":"I Watt","year":"1984","unstructured":"Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia. 1984, 39: 973-981. 10.1111\/j.1365-2044.1984.tb08885.x.","journal-title":"Anaesthesia"},{"key":"122_CR45","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJM198405313102202","volume":"310","author":"RL Wagner","year":"1984","unstructured":"Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D: Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984, 310: 1415-1421. 10.1056\/NEJM198405313102202.","journal-title":"N Engl J Med"},{"key":"122_CR46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","volume":"347","author":"I Issemann","year":"1990","unstructured":"Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990, 347: 645-650. 10.1038\/347645a0.","journal-title":"Nature"},{"key":"122_CR47","first-page":"3198","volume":"9","author":"Z Yang","year":"2003","unstructured":"Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R: HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res. 2003, 9: 3198-3203.","journal-title":"Clin Cancer Res"},{"key":"122_CR48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/bbrc.2000.2303","volume":"269","author":"R Yamada","year":"2000","unstructured":"Yamada R, Sano H, Hla T, Hashiramoto A, Kawahito Y, Mukai S, Kohno M, Tsubouchi Y, Inoue M, Komatsu A, Inoue K, Kondo M: Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis. Biochem Biophys Res Commun. 2000, 269: 415-421. 10.1006\/bbrc.2000.2303.","journal-title":"Biochem Biophys Res Commun"},{"key":"122_CR49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cdp.2008.05.008","volume":"32","author":"D Nagata","year":"2008","unstructured":"Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K: Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev. 2008, 32: 259-266. 10.1016\/j.cdp.2008.05.008.","journal-title":"Cancer Detect Prev"},{"key":"122_CR50","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00432-007-0277-y","volume":"133","author":"IA Voutsadakis","year":"2007","unstructured":"Voutsadakis IA: Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J Cancer Res Clin Oncol. 2007, 133: 917-928.","journal-title":"J Cancer Res Clin Oncol"},{"key":"122_CR51","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","volume":"8","author":"AP Heaney","year":"2002","unstructured":"Heaney AP, Fernando M, Yong WH, Melmed S: Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002, 8: 1281-1287. 10.1038\/nm784.","journal-title":"Nat Med"},{"key":"122_CR52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI0214264","volume":"109","author":"AP Heaney","year":"2002","unstructured":"Heaney AP, Fernando M, Melmed S: Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest. 2002, 109: 277-283. 10.1172\/JCI0214264.","journal-title":"J Clin Invest"},{"key":"122_CR53","first-page":"51","volume":"26","author":"A Gruszka","year":"2005","unstructured":"Gruszka A, Kunert-Radek J, Pawlikowski M: Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro. Neuro Endocrinol Lett. 2005, 26: 51-54.","journal-title":"Neuro Endocrinol Lett"},{"key":"122_CR54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1500863","volume":"150","author":"F Bogazzi","year":"2004","unstructured":"Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, Cosci C, Gasperi M, Bartalena L, Martino E: PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 2004, 150: 863-875. 10.1530\/eje.0.1500863.","journal-title":"Eur J Endocrinol"},{"key":"122_CR55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","volume":"151","author":"B Ambrosi","year":"2004","unstructured":"Ambrosi B, Dall\u2019Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P: Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing\u2019s disease. Eur J Endocrinol. 2004, 151: 173-178. 10.1530\/eje.0.1510173.","journal-title":"Eur J Endocrinol"},{"key":"122_CR56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2265.2005.02285.x","volume":"63","author":"S Cannavo","year":"2005","unstructured":"Cannavo S, Arosio M, Almoto B, Dall\u2019Asta C, Ambrosi B: Effectiveness of long-term rosiglitazone administration in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf). 2005, 63: 118-119. 10.1111\/j.1365-2265.2005.02285.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"122_CR57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2265.2005.02193.x","volume":"62","author":"SS Hull","year":"2005","unstructured":"Hull SS, Sheridan B, Atkinson AB: Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing\u2019s syndrome. Clin Endocrinol (Oxf). 2005, 62: 259-261. 10.1111\/j.1365-2265.2005.02193.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"122_CR58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","volume":"64","author":"GF Pecori","year":"2006","unstructured":"Pecori GF, Scaroni C, Arvat E, Martin M, Giordano R, Albiger N, Leao AA, Picu A, Mantero F, Cavagnini F: Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf). 2006, 64: 219-224. 10.1111\/j.1365-2265.2006.02452.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"122_CR59","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","volume":"90","author":"D Suri","year":"2005","unstructured":"Suri D, Weiss RE: Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing\u2019s disease. J Clin Endocrinol Metab. 2005, 90: 1340-1346. 10.1210\/jc.2004-1746.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR60","unstructured":"European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. 2013, EMA\/458028\/2013, London"},{"key":"122_CR61","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI110903","volume":"71","author":"DS Loose","year":"1983","unstructured":"Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D: Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983, 71: 1495-1499. 10.1172\/JCI110903.","journal-title":"J Clin Invest"},{"issue":"5","key":"122_CR62","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T: Ketoconazole in Cushing\u2019s disease: is it worth a try?. J Clin Endocrinol Metab. 2014, 99 (5): 1623-30. 10.1210\/jc.2013-3628.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T: Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol. 2008, 158: 91-99. 10.1530\/EJE-07-0514.","journal-title":"Eur J Endocrinol"},{"key":"122_CR64","volume-title":"Harrison\u2019s Principles of Internal Medicine: vol 18","author":"AS Fauci","year":"2011","unstructured":"Fauci AS, Longo DL, Hauser SL, Jameson JL, Loscalzo J, Kasper DL: Disorders of the Anterior Pituitary and Hypothalamus. Harrison\u2019s Principles of Internal Medicine: vol 18. 2011, Chapter 339, Page 2897-2899; 2011; ISBN 978-0-07174889-6"},{"key":"122_CR65","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart P, Montori VM: The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008, 93: 1526-1540. 10.1210\/jc.2008-0125.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR66","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M: Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008, 93: 2454-2462. 10.1210\/jc.2007-2734.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR67","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.4172\/1948-5956.1000e108","volume":"4","author":"CM Telleria","year":"2012","unstructured":"Telleria CM: Drug repurposing for cancer therapy. J Cancer Sci Ther. 2012, 4: ix-xi. 10.4172\/1948-5956.1000e108.","journal-title":"J Cancer Sci Ther"},{"key":"122_CR68","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","volume":"21","author":"IM Spitz","year":"2009","unstructured":"Spitz IM: Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009, 21: 318-324. 10.1097\/GCO.0b013e32832e07e8.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"122_CR69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-11-207","volume":"11","author":"CR Tieszen","year":"2011","unstructured":"Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM: Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 2011, 11: 207-10.1186\/1471-2407-11-207.","journal-title":"BMC Cancer"},{"key":"122_CR70","first-page":"369","volume":"23","author":"Y Liang","year":"2003","unstructured":"Liang Y, Hou M, Kallab AM, Barrett JT, El EF, Schoenlein PV: Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol. 2003, 23: 369-380.","journal-title":"Int J Oncol"},{"key":"122_CR71","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0090-9556(25)05972-0","volume":"5","author":"F Martz","year":"1977","unstructured":"Martz F, Straw JA: The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o, p\u2019-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos. 1977, 5: 482-486.","journal-title":"Drug Metab Dispos"},{"key":"122_CR72","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007, 356: 2372-2380. 10.1056\/NEJMoa063360.","journal-title":"N Engl J Med"},{"key":"122_CR73","unstructured":"European Public Assessment Report (EPAR) Signifor. 2012, EMEA\/H\/C\/002052, London"},{"key":"122_CR74","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/13543784.2010.495943","volume":"19","author":"G Arnaldi","year":"2010","unstructured":"Arnaldi G, Boscaro M: Pasireotide for the treatment of Cushing\u2019s disease. Expert Opin Investig Drugs. 2010, 19: 889-898. 10.1517\/13543784.2010.495943.","journal-title":"Expert Opin Investig Drugs"},{"key":"122_CR75","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM: A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012, 366: 914-924. 10.1056\/NEJMoa1105743.","journal-title":"N Engl J Med"},{"key":"122_CR76","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"122_CR77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.6061\/clinics\/2012(Sup01)20","volume":"67","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K: Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo). 2012, 67 (Suppl 1): 119-123. 10.6061\/clinics\/2012(Sup01)20.","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"122_CR78","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jvim.12303","volume":"28","author":"C Arenas","year":"2014","unstructured":"Arenas C, Melian C, Perez-Alenza MD: Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment. J Vet Intern Med. 2014, 28 (2): 473-80. 10.1111\/jvim.12303.","journal-title":"J Vet Intern Med"},{"key":"122_CR79","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ecl.2012.08.002","volume":"41","author":"CA Stratakis","year":"2012","unstructured":"Stratakis CA: Cushing syndrome in pediatrics. Endocrinol Metab Clin North Am. 2012, 41: 793-803. 10.1016\/j.ecl.2012.08.002.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"122_CR80","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1210\/jc.2013-1123","volume":"98","author":"MF Keil","year":"2013","unstructured":"Keil MF: Quality of life and other outcomes in children treated for Cushing syndrome. J Clin Endocrinol Metab. 2013, 98: 2667-2678. 10.1210\/jc.2013-1123.","journal-title":"J Clin Endocrinol Metab"},{"key":"122_CR81","unstructured":"German Disease Management Guideline Therapy of Type 2 Diabetes - long recension. 1st edition, Version 2. 2013"},{"key":"122_CR82","unstructured":"German Disease Management Guideline Prophylaxis, Diagnosis and Treatment of Osteoporosis - long version. 2009"},{"key":"122_CR83","unstructured":"German Disease Management Guideline Depressive Disorder - long version. 1st edition, Version 3. 2012"},{"key":"122_CR84","unstructured":"German Disease Management Guideline Arterial hypertension. 2008"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-014-0122-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0122-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:55:59Z","timestamp":1746323759000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-014-0122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1186\/s13023-014-0122-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"article-number":"122"}}